ANVSAnnovis Bio, Inc.

NYSE annovisbio.com


$ 7.60 $ 0.75 (10.95 %)    

Tuesday, 14-May-2024 12:49:57 EDT
QQQ $ 443.69 $ -1.17 (-0.26 %)
DIA $ 394.27 $ -0.82 (-0.21 %)
SPY $ 520.98 $ -1.20 (-0.23 %)
TLT $ 90.80 $ 0.19 (0.21 %)
GLD $ 217.93 $ 0.09 (0.04 %)
$ 6.85
$ 7.34
$ 0.00 x 0
$ 0.00 x 0
$ 7.29 - $ 7.60
$ 4.79 - $ 22.49
589,333
na
74.15M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-02-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-03-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 03-25-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-annovis-bio-lowers-price-target-to-23

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target ...

 annovis-bio-ceo-outlines-next-steps-in-alzheimers-research-after-mixed-phase-iiiii-trial-results

Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing n...

 canaccord-genuity-maintains-buy-on-annovis-bio-lowers-price-target-to-26

Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $36 ...

 hc-wainwright--co-reiterates-buy-on-annovis-bio-maintains-30-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $30 price tar...

 why-is-alzheimers-focused-annovis-bio-stock-nosediving-on-monday

Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite sl...

 annovis-bio-shares-resume-trading
Annovis Bio Shares Resume Trading
04/29/2024 14:46:33

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION